Prolactinoma is a pituitary adenoma secreting prolactin, arising from the lactotrophs of the anterior pituitary, and represents the most frequent cause of persistent pathological hyperprolactinemia. The biological peculiarity of this functional neoplasm is that hormonal excess is not merely a laboratory finding, but a signal capable of systematically disrupting reproductive physiology through inhibition of the pulsatility of GnRH and therefore of LH and FSH secretion. This results in a picture of hypogonadotropic hypogonadism with clinical effects that, in women, mainly manifest as menstrual disturbances and infertility and, in men, as sexual dysfunction and reduced gonadal function, often with later diagnosis.
Clinically, prolactinoma is a “dual-track” condition: on one side, the endocrine impact of hyperprolactinemia and secondary hypogonadism; on the other, the possible presence of a sellar mass with compressive effects on the optic chiasm and parasellar structures. Modern management is based on understanding dopaminergic control of prolactin and on the high efficacy of dopamine agonists, especially cabergoline, in normalizing prolactin and reducing tumor volume in most cases.
Prolactinoma is the most common functioning pituitary adenoma and accounts for a substantial proportion of pituitary tumors in the general population. Its observed frequency depends on the setting: in pituitary disease registries and infertility pathways, prevalence appears higher than in the general population, because reproductive symptoms more often lead to prolactin measurement and therefore to tumor identification. This aspect is crucial to understand that the epidemiology of prolactinoma partly reflects the probability of clinical detection, in addition to the true biological incidence.
The distribution by sex and age shows a tendency toward more frequent diagnosis in women of reproductive age, especially for microadenomas, whereas in men diagnosis often occurs later and with a higher proportion of large lesions. This difference does not necessarily imply intrinsically more aggressive biology in males, but is consistent with a less specific initial clinical presentation and with diagnostic delay related to the lower visibility of early signs of hypogonadism compared with menstrual disturbances.
From the perspective of risk factors, prolactinoma has no defined environmental determinants comparable to many epithelial neoplasms. Most cases are sporadic and arise without an identifiable external cause. However, a minority occurs within predisposing genetic syndromes, in which the development of pituitary adenomas is part of a broader picture of endocrine neoplasia or tumor predisposition. In these settings, risk is not linked to exposures, but to a genetic background that favors pituitary tumorigenesis.
It is useful to distinguish true biological risk factors from factors that increase the probability of “labeling” a condition as prolactinoma when it is not. Dopamine-antagonist medications, primary hypothyroidism and chronic renal failure can sustain even marked hyperprolactinemia without a secreting adenoma, whereas the stalk effect in the presence of non-secreting sellar masses can produce hyperprolactinemia secondary to reduced dopaminergic inhibition. In addition, macroprolactin can cause laboratory hyperprolactinemia with limited clinical relevance. These elements do not increase the probability of developing a prolactinoma, but they increase the risk of an incorrect diagnostic pathway if the pathophysiology of prolactin elevation is not reconstructed.
Finally, a relevant epidemiological concept concerns natural history: most prolactinomas have benign biological behavior, but there is a spectrum of presentations that includes invasive macroadenomas, cases resistant to dopamine agonists and forms with a greater clinical burden. In practice, “clinically significant” epidemiology is therefore driven not only by the presence of the tumor, but by the combination of size, secretion, compressive effects and response to medical therapy, which determines the complexity of long-term follow-up.
Prolactinoma derives from clonal proliferation of pituitary lactotrophs with prolactin hypersecretion. Its pathophysiological significance is understood by starting from the normal regulation of the lactotroph axis: prolactin is maintained at basal levels mainly by hypothalamic dopaminergic inhibition, which acts on dopaminergic receptors of lactotrophs by reducing synthesis and release of the hormone. In this scenario, prolactinoma represents tissue that, although it often retains a certain sensitivity to dopaminergic restraint, produces excess prolactin because of increased secreting mass and alterations in intracellular lactotroph regulation.
From an etiological standpoint, in most patients no single causal factor can be identified. Pituitary tumorigenesis is considered the result of molecular events that favor growth and survival of the lactotroph clone, with modulation of signaling pathways and cell-cycle control. In a minority of cases, prolactinoma is associated with hereditary syndromes characterized by predisposition to endocrine tumors, in which the occurrence of pituitary adenomas is part of a broader biological pattern and requires targeted clinical assessment.
The systemic pathophysiology of prolactinoma is dominated by the ability of elevated prolactin to interfere with the hypothalamic pituitary gonadal axis. Prolactin excess reduces pulsatile secretion of GnRH, causing a decrease in LH and FSH and therefore in gonadal function. In women, the consequence is anovulation and reduced ovarian production of estrogens and progesterone, with oligomenorrhea or amenorrhea and infertility. In men, reduced gonadotropin secretion impairs testicular steroidogenesis and spermatogenesis, leading to clinical hypogonadism and infertility.
A second pathophysiological axis concerns the breast, where prolactin promotes differentiation and secretory activity. In prolactinoma, galactorrhea is a possible but not mandatory manifestation: its presence depends on the sensitivity of breast tissue, the estrogenic environment and the interaction with other hormones. In many patients, especially in males and in women with reduced estrogenic tone, galactorrhea may be absent despite elevated prolactin, making the clinical picture not reducible to a linear dose-effect relationship.
In macroprolactinomas, tumor mass introduces an additional pathophysiological component. Sellar and parasellar growth can compress the optic chiasm, causing visual field disturbances, and can impair residual pituitary parenchyma, leading to deficiencies of other pituitary hormones. This dynamic is fundamental because it explains why some patients do not present with dominant reproductive symptoms, but with headache, visual disturbances or signs of hypopituitarism.
Finally, two aspects condition the pathophysiological interpretation of prolactin levels. The first is possible analytical underestimation in macroadenomas with very high prolactin if the sample is not diluted, with the risk of interpreting an actually extreme hyperprolactinemia as “moderate”. The second is macroprolactinemia, which can simulate increased secretion in immunoassay without corresponding biological activity. In true prolactinoma, biologically active monomeric prolactin is the relevant component, and its clinical impact derives from its ability to suppress the gonadal axis and sustain typical symptoms.
The clinical presentation of prolactinoma is determined by three overlapping dimensions: hyperprolactinemia with secondary hypogonadism, effects on breast tissue and, in larger tumors, compressive effects. Expression varies with sex and age and may be influenced by the duration of the disorder, because many consequences of hypogonadism emerge progressively and may be underestimated for years.
In women of reproductive age, the most typical picture includes menstrual irregularities up to amenorrhea, anovulation and infertility. Reduced estrogenic tone may be associated with vaginal dryness, dyspareunia and decreased sexual desire, whereas galactorrhea may be present as a sign of lactotroph hyperactivity, although it is not necessary to suspect the diagnosis. In some patients, onset is subtle and is detected only during an evaluation for pregnancy, when anovulation becomes the dominant clinical finding.
In males, presentation is often later. The patient may report reduced libido, erectile dysfunction, infertility and reduced physical energy, with a picture that may initially be interpreted as nonspecific. Delayed diagnosis increases the probability that the tumor is already larger at the time of identification, and therefore that mass-related symptoms such as headache or visual disturbances coexist. In this population, more marked impairment of gonadal function and a higher risk of complications related to prolonged hypogonadism are also more likely.
In macroprolactinomas, worsening headache and visual abnormalities, especially visual field defects, may be the main manifestation. In these cases, clinical evaluation must include active search for signs of hypopituitarism, because compression of the pituitary parenchyma can reduce secretion of other pituitary hormones and substantially modify therapeutic urgency and strategy.
In the long term, many manifestations derive from sex steroid deficiency rather than from prolactin excess itself. Chronic reduction in estrogens or androgens favors loss of bone mass with risk of osteopenia and osteoporosis, modifies body composition and may contribute to neuropsychiatric symptoms such as reduced well-being, asthenia and mood disturbances. These consequences are particularly relevant when diagnosis occurs after years of unrecognized hypogonadism.
A rare but clinically important event is pituitary apoplexy, which may manifest with severe acute headache, nausea, visual disturbances and clinical instability. Although not specific to prolactinoma, its possibility must be considered in the face of sudden worsening in a patient with known or suspected adenoma. Finally, in specific settings such as pregnancy, especially in patients with macroadenomas, tumor dynamics may change and require targeted clinical monitoring to detect compressive symptoms early.
Suspicion of prolactinoma arises when persistent hyperprolactinemia is associated with a compatible clinical phenotype and when the main alternative causes are unlikely. In women, the combination of persistent amenorrhea or oligomenorrhea, infertility and sometimes galactorrhea requires prolactin measurement as an essential step in endocrine assessment. Suspicion is strengthened when the picture is accompanied by signs of hypoestrogenism, because this suggests functional suppression of the gonadal axis rather than a simple isolated menstrual disorder.
In males, suspicion must be active in the presence of sexual dysfunction and reduced desire associated with biochemical hypogonadism with non-elevated gonadotropins, or in the presence of infertility with unexplained reduction in gonadal function. Since presentation may be nonspecific, suspicion must increase significantly if headache, visual disturbances or signs of hypopituitarism coexist, as these point toward a larger sellar lesion.
A central part of suspicion is reconstruction of possible confounders. Medications that increase prolactin can perfectly mimic the clinical picture of prolactinoma and, if not recognized, can lead to unnecessary imaging or erroneous interpretation of incidental microlesions. Similarly, primary hypothyroidism and renal failure can sustain persistent prolactin elevation. In these scenarios, suspicion of prolactinoma must remain “open” but should not be the first conclusion, because the clinically correct criterion is to demonstrate that hyperprolactinemia is not explained by more frequent and reversible causes.
Suspicion must also include two situations of clinical and laboratory discordance. A patient with elevated prolactin but few or no symptoms should raise consideration of macroprolactin. Conversely, a large sellar mass with prolactin that is not particularly elevated requires caution because it may reflect analytical underestimation if sample dilutions are not requested. In both cases, reasoned suspicion is not the search for a label, but the construction of a pathway that prevents classification errors and therefore inappropriate therapeutic choices.
In summary, prolactinoma should be suspected when hyperprolactinemia is confirmed, clinically consistent with secondary hypogonadism and not explained by pharmacological or systemic causes, or when the association with symptoms from a sellar mass suggests a functioning or potentially compressive pituitary lesion. Correct suspicion is the step that enables timely diagnosis and preserves reproductive function and neurological safety in at-risk cases.
The diagnosis of prolactinoma requires a pathway that demonstrates persistent biologically active hyperprolactinemia and identifies a secreting pituitary adenoma, distinguishing it from the stalk effect and from other causes of hyperprolactinemia. The correct sequence integrates biochemical confirmation, exclusion of alternative causes and sellar imaging, avoiding transformation of a single elevated value into a tumor diagnosis without verification steps.
The first level is confirmation of hyperprolactinemia with a repeated measurement interpreted in the clinical context. It is essential to exclude pregnancy in women of childbearing age and to reconstruct sampling conditions, because acute stress, sleep and exercise can transiently increase prolactin. In parallel, laboratory assessment must include thyroid function and evaluation of renal function, because primary hypothyroidism and chronic renal failure can sustain persistent increases. Gonadal status with sex steroids and gonadotropins makes it possible to document hypogonadotropic hypogonadism, which is the most clinically relevant effect of biologically active hyperprolactinemia.
A decisive step is screening for macroprolactin when symptoms are scarce or when clinical coherence is weak. Distinguishing monomeric prolactin from high-molecular-weight forms reduces the risk of diagnosing prolactinoma in a patient who actually has laboratory hyperprolactinemia with limited biological impact. This point is particularly important because many pituitary microadenomas are incidental findings and their presence does not automatically prove pathological prolactin secretion.
Medication review is mandatory and must be structured: molecule, dose, duration, timing relative to symptom onset, polytherapy and possible alternatives. The diagnosis of prolactinoma cannot be separated from exclusion of a medication-related etiology when the patient is taking medications known to increase prolactin, because in these cases the priority is to understand whether hyperprolactinemia is iatrogenic and whether any sellar finding is incidental.
According to the Endocrine Society guidelines and the international consensus of the Pituitary Society, to diagnose prolactinoma and establish a correct pathway it is necessary to:
Key elements of the diagnostic pathway
When hyperprolactinemia is confirmed and not explained by alternative causes, pituitary magnetic resonance imaging with sellar study is the decisive examination to identify the adenoma and define its size, extension and relationship with the optic chiasm. In macroadenomas or lesions close to the chiasm, ophthalmological evaluation with visual field testing is an integral part of assessment, because the presence of visual impairment modifies therapeutic urgency and priorities. In parallel, especially in macroadenomas, it is necessary to evaluate the other pituitary axes to identify associated deficiencies requiring specific treatment.
Differential diagnosis must distinguish prolactinoma from the stalk effect: both conditions can present with hyperprolactinemia and a sellar mass, but the pathophysiology is different and therefore so is the clinical strategy. Moreover, distinguishing prolactinoma from pharmacological hyperprolactinemia with an incidental microadenoma is a crucial pragmatic step to avoid improper diagnoses. Correct diagnosis, therefore, is not a single test, but the coherent convergence of biochemistry, clinical findings and imaging in a pathophysiologically plausible picture.
The classification of prolactinoma is clinically useful because it integrates anatomy, secretion and risk of complications. The first level is dimensional, distinguishing microadenomas from macroadenomas. This distinction is relevant because macroadenomas have a higher probability of extrasellar extension and compressive effects, and therefore require closer monitoring and an approach that considers visual function and possible associated hypopituitarism. Microadenomas, instead, more often present with reproductive symptoms and rarely cause neurological complications.
A second level is functional, linked to the degree of hyperprolactinemia and, above all, to its effect on the gonadal axis. Clinical severity does not necessarily coincide with the absolute prolactin value, but with the presence and duration of hypogonadism and with possible bone or reproductive impairment. A microadenoma with prolonged amenorrhea and loss of bone mass may be more clinically “severe” than a macroadenoma that, although large, is detected early and treated with a rapid response.
It is also useful to distinguish forms with standard biological behavior from cases resistant or intolerant to dopamine agonists. Resistance, understood as failure to normalize prolactin and achieve adequate volumetric reduction despite appropriate therapy, identifies a category with different therapeutic needs, which may require dose escalation, multidisciplinary evaluations and, in selected cases, surgery or radiotherapy. Pharmacological intolerance can also determine alternative choices even in the presence of a biologically sensitive tumor.
A further classification axis is reproductive status, particularly in women planning pregnancy or already pregnant. In this scenario, tumor size and proximity to the optic chiasm take on priority significance, because they influence the risk of symptomatic growth and surveillance strategies. This classification is not a “special” variant, but a pathophysiological adaptation to pituitary plasticity and to the endocrine changes of pregnancy.
Finally, a complete classification includes the possible presence of associated pituitary deficiencies and the degree of radiological invasiveness. These elements describe the relationship of the tumor with critical structures and anticipate the complexity of follow-up and treatment. In this way, prolactinoma classification becomes an operational map linking endocrine phenotype, neurological risk and expected response to medical therapy.
Treatment of prolactinoma has clear objectives: to normalize or significantly reduce prolactin, restore gonadal function and fertility when desired, reduce tumor mass and prevent or resolve compressive effects. In most patients, first-line therapy is medical with dopamine agonists, because these medications act directly on lactotroph physiology by restoring dopaminergic control and often obtaining tumor volume reduction in addition to biochemical correction.
Cabergoline is generally considered the reference treatment for efficacy and tolerability in most contexts, with the possibility of progressive titration. Bromocriptine remains an effective option, with broad historical experience and a still relevant role in selected scenarios, including management of patients who do not tolerate cabergoline or in particular reproductive circumstances. Choice and titration must be individualized, because response is influenced by tumor size, prolactin level, adherence and biological variability of the tumor.
Monitoring of response occurs on two levels: biochemical and radiological. Prolactin normalization and recovery of gonadal function represent immediate clinical outcomes, whereas volumetric reduction, especially in macroadenomas, is fundamental for visual safety. In patients with visual field impairment, response to medical therapy may be rapid and clinically significant, often making urgent surgery avoidable if visual recovery is timely and stable.
Management of adverse effects of dopamine agonists is an integral part of treatment. Nausea, dizziness and orthostatic hypotension can limit adherence, but often improve with slow titration and optimized administration. In some patients, neuropsychiatric effects or impulse control disorders may occur, requiring careful clinical evaluation and risk-benefit balancing. In settings of higher doses and prolonged treatment, assessment of cardiac valvular risk becomes a safety element and may guide personalized follow-up.
In cases of resistance or intolerance to medical therapy, the approach must be multidisciplinary. Dose escalation may be effective in some resistant patients, but when response remains insufficient or when tolerability prevents adequate therapy, transsphenoidal surgery represents the next option, especially if compressive effects exist, if reproductive desire cannot be managed pharmacologically or if decompression is needed. Radiotherapy is reserved for selected scenarios, with awareness of the long-term risk of hypopituitarism and of the latency of therapeutic effect.
In women who desire pregnancy, treatment aims to restore ovulation and normalize prolactin, in order to favor fertility and reduce the risk of tumor growth during gestation. Medical therapy is generally the first choice and requires specific counselling, especially in macroadenomas or lesions close to the optic chiasm. During pregnancy, strategy depends on tumor size, symptoms and visual risk, balancing minimization of pharmacological exposure with protection of neurological function when the risk of growth is significant.
In all cases, effective treatment does not coincide only with numerical normalization of prolactin, but with interruption of the pathophysiological sequence leading to hypogonadism, infertility and bone complications, and with management of the anatomical component of the tumor when present. This integrated approach is the key to achieving a stable long-term outcome.
Follow-up of prolactinoma must be built on tumor size, response to dopamine agonists and the patient’s clinical objectives. The three pillars of monitoring are prolactin, gonadal function and anatomical safety of the sellar region, with particular attention to the optic chiasm in macroadenomas. Effective follow-up documents not only efficacy, but also stability of response, because biochemical recurrences or tumor regrowth can occur especially after therapy withdrawal or reduction.
In the initial phases of medical therapy, prolactin checks guide pharmacological titration and allow evaluation of response speed. Clinical recovery of gonadal function, with resumption of ovulatory cycles or improvement of hypogonadal symptoms, is an important functional indicator because it reflects reactivation of the hypothalamic pituitary gonadal axis. In patients pursuing fertility, follow-up must include specific assessment of reproductive response and collaboration with reproductive medicine when needed.
Pituitary imaging with magnetic resonance imaging is particularly important in macroadenomas, to document volumetric reduction and stability over time, and to evaluate possible invasiveness. In patients with visual impairment or a lesion close to the chiasm, visual field testing and neuro-ophthalmological evaluation are an integral part of follow-up because the priority clinical risk is visual function. Rapid improvement after medical therapy confirms the appropriateness of the approach, whereas worsening requires urgent reassessment of the therapeutic plan.
Surveillance of global pituitary function is essential in macroadenomas. Tumor reduction can improve compression-related hypopituitarism, but pre-existing unrecognized deficiencies may also emerge. Therefore, follow-up must include evaluation of the other pituitary axes when clinically indicated, avoiding “single-topic” management centered only on prolactin.
Skeletal health must be monitored in patients with prolonged hypogonadism, especially if diagnosis is late or if recovery of gonadal function is slow. Bone densitometry and fracture-risk stratification become part of long-term follow-up, because bone loss is a silent and preventable complication if hypogonadism is corrected and risk factors are treated appropriately.
In some patients, after a prolonged period of prolactin normalization and radiological stability, controlled withdrawal of dopamine agonists may be considered. In this scenario, follow-up must initially be closer to detect early biochemical recurrences and assess whether remission is stable. The decision is not based on a single parameter, but on the combination of response duration, residual size and clinical context.
During pregnancy, follow-up requires a dedicated framework. In women with microadenomas and low risk, surveillance is mainly clinical, whereas in macroadenomas or lesions close to the chiasm, closer monitoring of symptoms and, when indicated, visual function is necessary, with therapeutic strategies ready to be reactivated in case of symptomatic growth. This approach reduces neurological risk without introducing excessive medicalization when biological risk is low.
The prognosis of prolactinoma is generally favorable because most tumors respond to dopamine agonists with reduction of prolactin and tumor volume and with recovery of gonadal function. Functional outcome depends critically on the timeliness of diagnosis and on the duration of hypogonadism before treatment, because many complications, particularly skeletal ones, are linked to the duration of exposure to estrogen or androgen deficiency.
In microadenomas, prognosis is usually excellent: compressive effects are rare and the main clinical objective is restoration of reproductive function and prevention of hypogonadism-related complications. In macroadenomas, prognosis also depends on anatomical response, because visual safety becomes a priority endpoint. A good response to medical therapy often reduces the need for surgery, whereas resistant cases require more complex strategies and prolonged follow-up.
The most relevant long-term complication is loss of bone mass with risk of osteopenia and osteoporosis, which derives from chronic hypogonadism more than from isolated prolactin excess. This complication is preventable with early diagnosis and effective treatment, but may persist if diagnosis is late or if therapeutic adherence is insufficient. On the reproductive level, infertility and gonadal dysfunction are frequent but often reversible, especially when prolactin is normalized and the gonadal axis resumes physiological dynamics.
Complications related to tumor mass include visual disturbances, headache and compression-related hypopituitarism in macroadenomas. A rare but severe acute event is pituitary apoplexy, which requires timely recognition. In patients with invasive macroadenomas treated with dopamine agonists, an uncommon but clinically important complication is cerebrospinal fluid rhinorrhea, related to rapid changes in the tumor and sellar anatomy, which requires specialist evaluation.
Therapeutic complications include adverse effects of dopamine agonists, which can limit adherence and therefore outcome stability. In long-term management, tolerability becomes part of functional prognosis. In case of surgery or radiotherapy, the main complication over time is hypopituitarism, which requires ongoing endocrine surveillance and replacement therapy when necessary.
In conclusion, prolactinoma is a highly treatable condition in most cases, with recovery of reproductive function and reduction in the risk of complications when the diagnostic approach is correct and therapy is maintained with adequate follow-up. Prognosis worsens mainly in resistant invasive macroadenomas, in cases with delayed diagnosis and in situations in which hypogonadism persists for a long time, because in these scenarios the burden of neurological and skeletal complications increases.